CRNX Crinetics Pharmaceuticals, Inc.

CIK 0001658247 50 ready 8-Ks latest July 10, 2026, 4:01 PM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline Risk accumulating: auditor change (2)

Ready 8-Ks 50

Latest filing July 10, 2026, 4:01 PM ET

Top materiality 0.90

Event mix other_material ×21 · earnings ×12 · leadership ×8

Sentiment 18 pos · 2 neg · 30 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CRNX

Highest-materiality recent filing

Vertex to acquire Crinetics for $85/share, ~$10B equity value, adding PALSONIFY and atumelnant

July 6, 2026, 5:17 PM ET M&A materiality 0.90 positive item 1.01 item 8.01 item 9.01

Vertex to acquire Crinetics for $85.00 per share in cash, total equity value ~$10.0B (~$8.8B net of cash).
Crinetics' PALSONIFY (once-daily oral for acromegaly) launched in 2025; atumelnant (ACTH receptor antagonist) in Phase 3 for CAH.

Read filing →

July 10, 2026, 4:01 PM ET M&A materiality 0.75 neutral item 1.01 item 5.02

Crinetics enters into merger agreement with Vertex Pharmaceuticals

Merger agreement signed July 6, 2026; Crinetics to become wholly owned subsidiary of Vertex.
July 6, 2026, 5:17 PM ET M&A materiality 0.90 positive item 1.01 item 8.01 item 9.01

Vertex to acquire Crinetics for $85/share, ~$10B equity value, adding PALSONIFY and atumelnant

Vertex to acquire Crinetics for $85.00 per share in cash, total equity value ~$10.0B (~$8.8B net of cash).
June 22, 2026, 4:16 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Crinetics shareholders elect three Class II directors, ratify PwC, approve say-on-pay

Elected Caren Deardorf (73.5M for), Weston Nichols (90.2M for), and Stephanie S. Okey (72.2M for) to 2029 terms.
May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Crinetics Q1 2026: PALSONIFY net revenue $10.3M; EU approval; net loss $127.8M

PALSONIFY net product revenue $10.3M in Q1 2026, up from $5.4M in Q4 2025; 232 enrollment forms received.
April 10, 2026, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Crinetics COO Jeff Knight resigns, enters consulting agreement at $400/hr

Jeff Knight resigned as Chief Development and Operating Officer effective April 10, 2026 (previously reported March 23, 2026).
March 23, 2026, 7:59 PM ET leadership materiality 0.60 negative item 5.02

Crinetics' Chief Development and Operating Officer resigns effective April 10, 2026

Jeff Knight resigns as Chief Development and Operating Officer, effective April 10, 2026.
March 3, 2026, 6:59 PM ET other material materiality 0.40 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

Crinetics Pharmaceuticals dismisses auditor BDO, appoints PwC

Audit Committee dismissed BDO on Feb 27, 2026; no disagreements or reportable events for FY2024/2025.
February 26, 2026, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion

PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.
January 26, 2026, 6:59 PM ET leadership materiality 0.15 neutral item 5.02 item 9.01

Crinetics changes Jeff Knight's title from COO to Chief Development and Operating Officer

Title change effective January 2, 2026; responsibilities expanded.
January 13, 2026, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 7.01 item 9.01

Crinetics reiterates preliminary Q4 2025 PALSONIFY net product revenue over $5.0M

Net product revenue from PALSONIFY (paltusotine) exceeds $5.0M for Q4 2025.
January 7, 2026, 6:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Crinetics prices $350M common stock offering at $45.95/share to fund PALSONIFY launch

Pricing: 7,620,000 shares at $45.95/share; gross proceeds ~$350M.
January 5, 2026, 6:59 PM ET other material materiality 0.85 positive item 2.02 item 7.01 item 8.01 item 9.01

Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction

Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.
December 17, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance

Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.
November 6, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval

PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.
September 26, 2025, 7:59 PM ET regulatory materiality 0.90 positive item 7.01 item 8.01 item 9.01

Crinetics gets FDA approval for PALSONIFY (paltusotine) as first oral acromegaly treatment

FDA approved PALSONIFY (paltusotine) for adults with acromegaly with inadequate response to surgery or not surgical candidates.
August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025

Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.
June 30, 2025, 7:59 PM ET other material materiality 0.50 neutral item 7.01 item 9.01

Crinetics to present 8 abstracts at ENDO 2025, including long-term paltusotine data and Phase 2 CAH results

Eight abstracts at ENDO 2025 (July 12-15, San Francisco) covering PALSONIFY (paltusotine), atumelnant, and CRN12755.
June 26, 2025, 7:59 PM ET other material materiality 0.60 neutral item 7.01 item 8.01 item 9.01

Crinetics R&D Day updates preclinical pipeline: TSHR antagonist, SST3 agonist, NDC platform

CRN12755 (TSHR antagonist) decreased thyroid hormone (T4) in rat model and hyaluronic acid/IL-6 in TED patient orbital fibroblasts.
June 12, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

Crinetics shareholders elect directors, ratify auditor, approve say-on-pay at annual meeting

Elected Class I directors R. Scott Struthers (69.6M for), Matthew K. Fust (67.6M for), and Rogério Vivaldi Coelho (68.9M for), each with ~3.6M broker non-votes.
May 8, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Crinetics Q1 net loss $96.8M; cash $1.3B; paltusotine PDUFA Sept 25, 2025

Net loss of $96.8M for Q1 2025 vs. $66.9M in Q1 2024, driven by higher R&D and SG&A costs.
April 4, 2025, 7:59 PM ET other material materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change

Former CFO Marc Wilson transitions to consultant role through April 2026

Wilson resigned as employee on April 1, 2025, and entered a consulting agreement through April 1, 2026, with a possible six-month extension.
February 27, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025

Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.
February 24, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Crinetics appoints Tobin Schilke as CFO effective Feb 28, 2025

Tobin Schilke appointed CFO effective February 28, 2025, succeeding Marc Wilson.
January 14, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025

Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.
January 10, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Crinetics' atumelnant Phase 2 CAH trial meets primary endpoint with up to 80% mean A4 reduction

Atumelnant reduced androstenedione up to 80% (120mg, p<0.0001); 80mg dose reduced by 774 ng/dL (p<0.0001).
December 16, 2024, 6:59 PM ET leadership materiality 0.65 positive item 5.02 item 7.01 item 9.01

Crinetics appoints Isabel Kalofonos as CCO ahead of paltusotine launch

Isabel Kalofonos named Chief Commercial Officer, effective Dec 16, 2024; leads paltusotine (once-daily SST2 agonist for acromegaly) launch prep and pipeline commercialization.
December 9, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

Crinetics announces FDA acceptance of NDA for paltusotine in acromegaly; PDUFA Sept 25, 2025

FDA accepted Crinetics' NDA for once-daily oral paltusotine for adult acromegaly patients.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Crinetics reports Q3 net loss $76.8M; submits NDA for paltusotine; raises $575M

Net loss of $76.8M in Q3 2024 vs $57.5M in Q3 2023; revenue $0 vs $0.3M from SKK licensing.
October 16, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01 ◈ executive_change

Crinetics COO James Hassard departs; consulting deal through Jan 2025 at $200/hr

James Hassard ceased as COO effective Oct 14, 2024; consulting and separation agreements signed Oct 10.
October 9, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Crinetics prices upsized $500M public offering at $50/share; net proceeds ~$472M

Pricing of 10,000,000 shares of common stock at $50.00/share for gross proceeds of $500.0 million.
September 26, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Crinetics submits NDA to FDA for paltusotine for acromegaly; Phase 3 data support submission

NDA supported by 18 clinical trials including two Phase 3 PATHFNDR studies; all primary and secondary endpoints met.
September 17, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

Crinetics CCO James Hassard to depart effective October 14, 2024

James Hassard separates as Chief Commercial Officer; last day October 14, 2024.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 5.02 item 9.01 ◈ executive_change

Crinetics Q2 net loss $74.1M; CFO Wilson departs; paltusotine NDA on track for H2 2024

Net loss of $74.1M in Q2 2024 vs $51.0M in Q2 2023; R&D expenses rose to $58.3M from $40.6M.
June 21, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Crinetics enters ATM equity offering agreement for up to $350M

Filed prospectus supplement registering up to $350M in common stock sales.
June 10, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

Crinetics shareholders re-elect directors, ratify auditor, approve NEO pay

Dr. Camille Bedrosian elected with 50.8M votes for (77%), 14.9M withheld; Dr. Wendell Wierenga with 50.3M for (76%).
June 3, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024

Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.
May 22, 2024, 7:59 PM ET other material materiality 0.50 neutral item 7.01 item 9.01

Crinetics announces early release of ENDO 2024 late-breaking abstracts for atumelnant Phase 2 CAH study

Late-breaking abstracts for atumelnant (CRN04894) Phase 2 CAH study released before embargo.
May 9, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Crinetics Q1 net loss $66.9M; paltusotine NDA on track for 2H 2024

Net loss of $66.9M in Q1 2024 vs $46.0M in Q1 2023; revenue fell to $0.6M from $2.7M.
May 8, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024

Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).
April 4, 2024, 7:59 PM ET other material materiality 0.20 neutral item 5.02

Crinetics adopts non-qualified deferred compensation plan for executives and directors

Plan effective April 1, 2024; allows deferral of salary, fees, bonuses, and time-based RSUs.
March 19, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Crinetics paltusotine meets all endpoints in Phase 3 acromegaly study; NDA planned 2H 2024

Primary endpoint: 56% of paltusotine patients achieved IGF-1 ≤1.0 xULN vs 5% placebo (p<0.0001).
March 12, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Crinetics reports positive Phase 2 results for paltusotine in carcinoid syndrome

Phase 2 trial: 63% reduction in mean flushing frequency (p<0.0001) for patients with >1/day at baseline.
March 1, 2024, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements

Crinetics raises $350M in oversubscribed private placement of 8.33M shares at $42/sh

Private placement of 8,333,334 common shares at $42.00/share raises ~$350M gross proceeds.
February 28, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Crinetics reports Q4 net loss of $60.1M; announces $350M private placement; paltusotine NDA on track for 2H 2024

Net loss for Q4 2023 was $60.1M vs $45.0M in Q4 2022; full-year net loss $214.5M vs $163.9M in 2022.
January 8, 2024, 6:59 PM ET other material materiality 0.65 neutral item 7.01 item 9.01

Crinetics outlines 2024 milestones: paltusotine Phase 3 data Q1, CRN04894 data Q2

Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly on track for topline data in Q1 2024.
December 18, 2023, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Crinetics reports positive initial Phase 2 data for paltusotine in carcinoid syndrome; 65% symptom reduction

65% reduction in excess bowel movements and 65% reduction in flushing frequency in evaluable patients.
December 12, 2023, 6:59 PM ET other materiality 0.15 neutral item 5.03 item 9.01 ◈ Governance Changes

Crinetics amends bylaws to adopt universal proxy rules and enhance stockholder proposal disclosures

Amended bylaws to comply with SEC universal proxy rules, requiring compliance with Rule 14a-19 for soliciting proxies.
November 7, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Crinetics reports Q3 net loss of $57.5M; Phase 3 acromegaly study met all endpoints

Phase 3 PATHFNDR-1: 83% paltusotine vs 4% placebo maintained IGF-1 ≤1xULN (p<0.0001); all secondary endpoints met.
September 13, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Crinetics upsizes public offering to $350M gross; prices 11.44M shares at $30.59

Priced upsized offering of 11,441,648 shares at $30.59 per share, expected gross proceeds ~$350M.
September 11, 2023, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Crinetics' oral paltusotine succeeds in Phase 3 PATHFNDR-1; 83% maintain IGF-1 vs 4% on placebo

Paltusotine met primary endpoint: 83% maintained IGF-1 ≤1.0xULN vs 4% on placebo (p<0.0001).